On June 9, 2022, Corvia Medical, Inc. closed the transaction. The company has received $13,734,351.7076 in its third tranche bringing total funding raised in the transaction to $54,000,000. The round of funding from returning investors like General Catalyst Group Management, LLC, Edwards Lifesciences Corporation, Lumira Ventures, Third Rock Ventures, LLC and Accelmed Partners.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
85.09 USD | -0.19% | -1.00% | +11.59% |
05-01 | Edwards Lifesciences Insider Sold Shares Worth $1,212,687, According to a Recent SEC Filing | MT |
04-30 | Edwards Lifesciences Insider Sold Shares Worth $622,062, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.59% | 51.37B | |
+8.06% | 218B | |
+6.94% | 184B | |
+13.54% | 135B | |
-0.27% | 62.38B | |
+7.76% | 50.9B | |
+1.14% | 40.87B | |
+3.21% | 36.28B | |
+26.11% | 31.88B | |
+17.81% | 24.39B |
- Stock Market
- Equities
- EW Stock
- News Edwards Lifesciences Corporation
- Corvia Medical, Inc. announced that it has received $54 million in funding from Accelmed Partners, Lumira Ventures, General Catalyst Group Management, LLC, Third Rock Ventures, LLC, Edwards Lifesciences Corporation, and other investors